Shifting trends in the pharmaceutical marketplace: What to watch March 31, 2017By Bryant FurlowFrom public furor over price hikes to the loss of patent protections for blockbuster drugs, big changes are afoot in the pharmaceutical marketplace. Read more. Incremental clinical advances for Duchenne Muscular Dystrophy March 31, 2017By Bryant FurlowJust last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more. Rapid oncology innovation raises management challenges for payers March 31, 2017By Bryant FurlowOncology is a complex and rapidly-evolving management challenge for payers. Top challenges likely to slow adoption of biosimilars March 31, 2017By Bryant FurlowBiosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption. Top considerations when determining whether to approve expensive drugs March 30, 2017By Bryant FurlowWeighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations. Expedited FDA approval plays dominant role in drug approvals March 30, 2017By Bryant FurlowLast year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017. What to do About Rising Health-Care Costs? March 30, 2017By Nicholas HammTaking a clear-eyed look at the cost of health care can reduce waste. What’s in the Specialty Pharmacy Pipeline?Biosimilars, cancer drugs, and orphan drugs are heading towards FDA approval in 2017.